

PHARMA COGNIZANCE


Current status of COVID-19 VACCINE



Dr. LEKSHMI R NATH

Assistant Professor, Department of Pharmacognosy

Vaccines are the best way to combat viral diseases that cause epidemics and pandemics throughout the world. They confer an optimal antiviral state to the host both activating the beneficial immune response and dampening its deleterious effects. The coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to public health. The



widespread threat of SARS-CoV-2 to humans has spawned challenges to develop safe and effective vaccines for preventive use. There are various stages for the development of novel vaccines starting from the exploratory stage of finding suitable candidates to the preclinical and clinical stages, finally regulatory reviewing and approval to the manufacturing and quality control. A variety of SARS-CoV-2 vaccine types are currently under

development, including inactivated vaccines, nucleic acid vaccines, adenovirus-based vector vaccines, and recombinant subunits vaccines. According to the World Health Organization (WHO), till now 172 vaccine candidates are under pre-clinical development, 64 are under clinical development and 9 vaccines are launched globally. Sputnik V is the first registered vaccine for COVID-19 which is approved in Russia with 91.4% effectiveness. Post marketing surveillance was done on 40,000 people in Belarus and Russia. mRNA-1273 is an mRNA based vaccine approved in Canada and the United States for emergency use in adults and the vaccine was found to be 94.5% effective. This vaccine candidate was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna, Inc., and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. BNT162b2 is



another mRNA based vaccine which was developed by Pfizer and BioNTech and was licensed by Shanghai Fosun Pharmaceutical (Group) Co., Ltd in China. It was found to be over 90% effective. The vaccine was launched in several countries including United Kingdom, United States, Bahrain, Mexico, Canada, Kuwait, Saudi Arabia, Oman, Singapore and the European Union. EpiVacCorona is a peptide vaccine developed by the Vektor State Research Center of Virology and Biotechnology early use in Russia. BBIBP-CorV is an inactivated vaccine developed by Sinopharm exhibits 79.4% efficacy. CoronaVac is an inactivated vaccine candidate developed and manufactured by the Chinese biopharmaceutical company Sinovac. The vaccine is approved in China for high-risk category individuals like Healthcare personnel during emergency situations with an efficacy of over 50%. Bharat Biotech developed COVAXIN, a whole-virion inactivated vaccine with an efficacy of 60% and is the first indigenous vaccine candidate of India. After successful completion of the interim analysis from the Phase 1 & 2, Bharat Biotech received DCGI approval for Phase 3 clinical trials of COVAXIN and it involves 26,000 participants across India. Recently Bharat Biotech applied for emergency use authorization for its indigenous COVID-19 vaccine to DCGI. The Serum Institute of India, the world's largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield, while Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). Covishield exhibited effectiveness of about 70.4%. Drug Controller General of India (DCGI) approved these two COVID-19 vaccines for restricted emergency use in the country with a recommendation that these vaccines have to be



administered in two doses and have to be stored at 2-8 degree Celsius. As companies across the globe are speeding up to bring an effective COVID vaccine, India's indigenous Covaxin in the country is likely to be available for the whole population in the first quarter of 2021.

The European Centre for Disease Prevention and Control (ECDC) announced that the rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations have been observed in the UK. The variant is significantly more transmissible than previously circulating variants, with an estimated increase in reproductive number (R) by 0.4 or greater with estimated increased transmissibility of up to 70 per cent. The new strain of the virus is known to have 13 mutations in the spike protein of which the N501Y mutation is responsible for it spreading 70 per cent faster than earlier versions

of the virus. As per Indian virology experts the new mutated variant called VUI-202012/01 is not clinically more severe but is 70 per cent more transmissible than previously circulating variants. However, it is also noted that there is no indication of increased infection severity observed related to the variant with multiple mutations in the spike protein. The new variant has mutations to the spike protein that the three leading vaccines are targeting namely Moderna, Pfizer and Oxford-AstraZeneca. However, vaccines produce antibodies against many regions in the spike protein. As the virus mutates significantly, current vaccines might no longer offer as much protection some times. But expert opinion suggests for maintaining social distancing and following good sanitation practices as well as good dietary habits for improving the immune system, which should be sufficient to tackle the new strain of COVID-19.

SL. NO	VACCINE NAME	MANUFACTURING COMPANY	CURRENT STATUS	APPROVED COUNTRIES	REFERENCE
1	<i>Sputnik V</i>	Gamaleya Research Institute Russia, Acellena Contract Drug Research and Development	Launched	Russia	https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
2	<i>mRNA-1273</i>	Moderna, Biomedical Advanced Research and Development Authority (BARDA) and National Institute of Allergy and Infectious Diseases (NIAID)	Launched	United States, Canada	https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
3	<i>BNT162b2</i>	Pfizer, BioNTech; Fosun Pharma	Launched	United Kingdom, United States, Bahrain, Mexico, Canada, Kuwait, Saudi Arabia, Oman, Singapore, European union	https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
4	<i>EpiVac Corona</i>	Federal Budgetary Research Institution State Research Center of Virology and Biotechnology Russia	Launched	Russia	https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker


SL. NO	VACCINE NAME	MANUFACTURING COMPANY	CURRENT STATUS	APPROVED COUNTRIES	REFERENCE
5	BBIBP-CorV	Beijing Institute of Biological Products ; China National Pharmaceutical Group (Sinopharm)	Launched	China, U.A.E	https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
6	CoronaVac	Sinovac	Launched	China	https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
7	No name (Inactivated Vaccine)	Wuhan Institute Of Biological Products (under Chinese Academy of Sciences); China National Pharmaceutical Group (Sinopharm)	Launched	China, U.A.E	https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
8	COVAXIN	Bharat Biotech; National Institute of Virology, ICMR	Launched	Restricted Emergency Use in India	https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
9	COVISHIELD	Serum Institute of India, Pune and based on the Oxford Astra Zeneca vaccine	Launched	Restricted Emergency use in India and the U.S	https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/

THRUST AREAS OF RESEARCH IN AMRITA SCHOOL OF PHARMACY

1. Nose to brain delivery
2. Nanomedicine in cancer and autoimmune diseases
3. Bio-nano interface
4. Pulmonary and transdermal drug delivery
5. Bioprospecting of active moieties from plants
6. Cancer biology & Phytomedicine
7. Multitargeted drug design in cancer and tuberculosis
8. Design and development of drugs for neurodegenerative disorders
9. Bioactive plant compounds against infectious diseases
10. Pharmacological evaluation of spices.
11. Enhancement of CNS drug delivery
12. Neurobehavioral pharmacology and child health
13. Therapeutic drug monitoring of anticancer drugs
14. Optimization of drug therapy in Oncology, Neurology etc.
15. Rational use of antibiotics in postsurgical patients



Scopus articles of 2020 from Amrita School of Pharmacy based on subject area (n=72)




Drug repurposing for chronic stress



ATHIRA KV et al.,
ACS Chemical Neuroscience 2020

Chronic stress is the leading cause of memory impairment today. Various stress-based models are being developed for studying cognitive impairment. Repurposing of existing drugs is the safest and cheapest option for treatment. Vorinostat (VOR) is the first histone deacetylase (HDAC) inhibitor approved by the U.S. FDA. The findings of the study reveal that VOR has the potential to reverse cognitive dysfunction due to

chronic stress via modulation of ER stress markers and histone deacetylase (HDAC2).




Drug delivery strategies for Keloids



KALADHAR K et al.,
Journal of Controlled Release, 2020

The available treatments are not promising in reducing the recurrent rate of keloids as there are chances of high re-occurrences with similar/larger lesions on the removed keloid site. The article highlights the importance of controlled angiogenesis with the help of controlled drug delivery strategies enabling the wound healing process without the induction of keloid.




Antidepressant potential and proposed mechanism of vorinostat



ATHIRA KV et al.,
Psychoneuroendocrinology 2020

The antidepressant potential of vorinostat (VOR) against chronic social defeat stress (CSDS) in mice was explored. Vorinostat attenuated chronic social defeat stress-induced neurobehavioral alterations in defeated mice. Vorinostat showed antidepressant-like responses via modulation of cytoplasmic HDAC6 level. An elevated hippocampal HDAC6 level in defeated mice was also observed, which was restored by VOR treatment




Hitting neurodegenerative disorders



MATHEW B et al.,
Chem Med Chem. 2020

A 1,3- benzodioxine chalcone derivative CD8 potently and non-selectively inhibited MAO-A and MAO-B (IC_{50} = 0.023 and 0.026 μ M, respectively). CD10 and CD8 effectively, competitively, and reversibly inhibited AChE with IC_{50} values of 5.40 and 9.57 μ M, respectively. CD8 and CD10 showed high adsorptions and blood brain barrier permeabilities via in silico analysis, and they can be considered potential dual-targeting inhibitors of MAO and AChE




Anti-cancer treatment modality by using Reverse Warburg effect



ANEESH TP et al.,
Medical Hypotheses. 2020

An old ideology of killing the cancer cells by starving them is the underlying concept of the Warburg effect. The concept of the Reverse Warburg effect proposes a new anti-cancer treatment modality by preventing the generation and transport of lactate through the inhibition of monocarboxylate transporters and in turn, arresting the cancer cells.




Multitarget inhibitor for neurodegenerative disorders




MATHEW B et al.,
ACS Combinatorial Science. 2020

Development of selective MAO-B inhibitors: Fourteen (hetero-)(arylidene)arylhydrazide derivatives (ABH1–ABH14) were synthesized, and their inhibitory activities against monoamine oxidases (MAOs) and acetylcholinesterase (AChE) were evaluated. Compound ABH5 most potently inhibited MAO-B with an IC_{50} value of $0.025 \pm 0.0019 \mu M$. ABH5 was shown to be a reversible competitive inhibitor for MAO-A and MAO-B with K_i values of 0.96 ± 0.19 and 0.024

$\pm 0.0077 \mu M$, respectively, suggesting that this molecule can be considered as an interesting candidate for further development as a multitarget inhibitor relating to neurodegenerative disorders.



Utilizing PI3K/Akt/mTOR pathway to combat liver cancer



NATH LR^{et al.},
Letters in Drug Design & Discovery 2020

A virtual screening method with phytochemicals of flavanoid category using BIOVIA Discovery Studio was performed. Molecular docking, molecular interaction and ADMET (absorption, distribution, metabolism, excretion and toxicity) analysis were used to identify the affinity between

selected phytoconstituents as mTORC1 inhibitor against Hepatocellular carcinoma (HCC). Kaempferol was having a better affinity towards the receptor FKBP12, a Rapamycin Binding Domain and AKT serine/threonine-protein kinase resulting in the mTORC1 inhibition in HCC.

Faculty Contributions



Dr. SABITHA M
Principal,
Amrita School of Pharmacy

Dr. Sabitha M was nominated as a member of the M.Pharm syllabus committee by the Pharmacy Council of India, New Delhi.



Ms. ANILA K N
Assistant Professor,
Department of Pharmacy Practice

Ms. Anila K N was a panelist in Part-IV Webinar series on Medication Safety' organised by Department of Pharmacology, AIMS on 22nd July 2020 and involved in a discussion on the topic 'Reacting to Reactions'.



Dr. UMA DEVI P
Associate Professor,
Department of Pharmacology

Dr. Uma Devi P was a panelist in Part-IV Webinar series on Medication Safety' organised by Department of Pharmacology, AIMS on 22nd July 2020 and involved in a discussion on the topic 'Levelling, drug Levels'.



Dr. M S SUDHEESH
Associate Professor, Department of Pharmaceutics

Dr M S Sudheesh was a resource person in a webinar organized by Surabhi College of Pharmacy, Bhopal in connection to World Pharmacist's day on 25th September 2020.

Dr. M.S. Sudheesh wrote an article for the 26th Issue of the Newsletter Nanotechnology into Reproductive Healthcare: From Molecules to Materials to Modalities published by Indian Society for the Study of Reproduction & Fertility (ISSRF). The title of the article is "Role of bio-nanointerface in nanomedicine".

Dr M S Sudheesh was a guest speaker in a AICTE sponsored short term training programme organized by Sagar Institute of Research and Technology, Bhopal on 23rd December 2020. He spoke on 'Challenges in cancer nanomedicine'



Dr. ANEESH T P

Associate Professor, Department of Pharmaceutical Chemistry and Analysis

Dr. Aneesh T P, was selected as a Pharm.D committee member for the Pharmacy Council of India (PCI). He was the Scientific Committee Chairman and Organising Committee Member in the Student Pharmaceutical Conclave organised by the Pharmacist Society of Kerala and Kerala Private Pharmacist's Association on 21st August 2021.

- He also participated as a Coordinating Member in the Inauguration of National Pharmacy Week Celebration and the launch of Pharma App organised by Kerala State Pharmacy Council on 16th November 2021.



Dr. BIJO MATHEW

Associate Professor, Department of Pharmaceutical Chemistry

Dr. Bijo Mathew, was appointed as a Guest Editor of the journal "Combinatorial Chemistry and High Throughput Screening" Bentham Science for its upcoming thematic issue.




Dr. KALADHAR KAMALASANAN

Assistant Professor, Department of Pharmaceutics

Dr. Kaladhar Kamalasanan is selected as an Executive Council member of Society for Biomaterials and Artificial Organs India (SBAOI) for a term of three years. The SBAOI society is a member of The International Union of Societies for Biomaterials Science and Engineering (IUSBSE).



Rajitha Panonnummal, Nitheesh Antony and M. Sabitha had contributed a Book chapter in "Hand book of chitin and chitosan" volume 3: Chitin and Chitosan based Polymer Materials for Various Applications published by Elsevier in June 2020, Pages 407-431 on topic "Drug delivery and tissue engineering applications of chitosan-based biomaterial systems"



CHAPTER	
17	
Drug delivery and tissue engineering applications of chitosan-based biomaterial systems	
Rajitha Panonnummal, Nitheesh Antony and M. Sabitha	
Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Coimbatore Health Sciences Campus, Coimbatore, India	
CONTENTS	
17.1 Introduction	407
17.1.1 Chitin/chitosan	407
17.1.2 Chitin/chitosan: Structure of chitin	407
17.1.3 Properties and applications of chitin	407
17.1.4 Properties and applications of chitosan	407
17.1.5 Properties of chitin and chitosan	407
17.2 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.1 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.2 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.3 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.4 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.5 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.6 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.7 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.8 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.9 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.10 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.11 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.12 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.13 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.14 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.15 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.16 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.17 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.18 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.19 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.20 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.21 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.22 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.23 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.24 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.25 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.26 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.27 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.28 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.29 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.30 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.31 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.32 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.33 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.34 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.35 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.36 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.37 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.38 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.39 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.40 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.41 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.42 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.43 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.44 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.45 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.46 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.47 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.48 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.49 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.50 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.51 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.52 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.53 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.54 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.55 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.56 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.57 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.58 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.59 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.60 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.61 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.62 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.63 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.64 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.65 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.66 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.67 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.68 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.69 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.70 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.71 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.72 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.73 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.74 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.75 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.76 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.77 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.78 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.79 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.80 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.81 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.82 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.83 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.84 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.85 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.86 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.87 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.88 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.89 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.90 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.91 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.92 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.93 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.94 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.95 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.96 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.97 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.98 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.99 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407
17.2.100 Chitin/chitosan derivatives in drug delivery of biomaterial systems	407

Students Achievements



Mr. Rohan Mishra of 2nd year M.Pharm Pharmaceutical Chemistry and Ms. Gopika R of 2nd year M.Pharm Pharmacology have been awarded BEST STUDENT SPEAKER in the Drug

Design & Synthesis Research and Pharmacological Research section respectively at the Students Pharmaceutical Conclave organized by the Pharmacist Society of Kerala in association with Kerala Private Pharmacists Association on 21st August, 2020.



Ms. Adithya J of 7th semester B.Pharm and Ms. Sonu Benny Ph.D scholar, were awarded 2nd prize in the Phytochemical Research and Drug Design & Synthesis Research section respectively at the

Students Pharmaceutical Conclave organized by the Pharmacist Society of Kerala in association with Kerala Private Pharmacists Association on August 21, 2020.



Ms. Rajalakshmi R, 4th year Pharm.D student secured the second prize in the quiz and video presentation competition in the "PHARMA-RENOW 2020" conducted on the

occasion on World Pharmacist Day, organized by Department of Clinical Pharmacy, St.Thomas Hospital, Chethipuzha, Kottayam, Kerala.



Ms. Shivali Kamath of 4th year Pharm.D participated in the "Patient Awareness Pamphlet Making Contest" organized by the Doctor of Pharmacy Association on September 22nd conducted on

the occasion of World Pharmacist Day celebration 2020. Her pamphlet was one among the 3 best pamphlets.



Ms. Sonu Benny, PhD scholar, Amrita School of Pharmacy secured first position in oral presentation in Drug Discovery Summit 2020, an International web conference on "Exploring

New Horizons in Drug Research, Discovery and Development" conducted by Baddi University of Emerging Sciences and technologies, in association with Chandigarh Region Innovation and Knowledge Cluster and CIPLA foundation on October 9 - 10, 2020.

Ms. Sonu Benny, PhD Scholar, Amrita School of Pharmacy secured first prize in SPEAK AND WIN COMPETITION organized by The Pharmacist Group in connection to World Pharmacist Day 2020 on the topic Role of Pharmacist in dispensing medicines.

Ms. Rajalakshmi R, 4th year Pharm D student bagged cash prize for standing first position in a 'Big Quiz-Link in Bio' on topic Basic human anatomy & Physiology conducted by Medroin.

Observance of epic day:



"Sri Peeyush is an excellent role model of Dharma & values for us as students in life"
— Ramya

**AMRITA** School of Pharmacy
VEDHYA VIDYAPEETHAM

RAMAYANA CELEBRATION 2020

WEBINAR ON
രാമായണത്തിന്റെ സമകാലീന വായന

Sri.Peeyush G, Motivational Speaker

Join Meeting :
meet.google.com/aof-dgpa-iyt

AUGUST 13 | THURSDAY | 11:00 AM IST



LIVE ON :  **GOOGLE MEET**

Amidst confronting the pandemic situation Amrita School of Pharmacy hosted cultural events virtually to inculcate spiritual and moral values in students. Significance of the epic 'Ramayana Month' was promulgated among the student community.

The enlightening session was handled by Sri.Peeyush.G, Motivational speaker.

HIGHLIGHTS:

- Discussion on the historic Puranas and interconnecting it with present-day situations.
- Elocution competition.
- Ramayana Chanting by cultural education faculty, Sri. Hariharan Iyer and two student representatives (Arya from Pharm D 2016 batch and Ms.Abhirami from B Pharm 2019 batch).

Virtual alumni meet -2020



An alumni meet of Pharm D 2012-18 batch of Amrita School of Pharmacy, was held on July 12th, 2020, via Google meet platform.

HIGHLIGHTS

- Many alumni & faculty attended the first virtual alumni meet.
- All the students shared their present employment details and working pattern in this corona pandemic times.

Pharmacists: Frontiers ensuring a Healthy India – Webinar on 5th September 2020

AMRITA
SCHOOL OF PHARMACY

WEBINAR ON
**PHARMACISTS: FRONTIERS
ENSURING A HEALTHY WORLD**

2020 SEPTEMBER 05

Time: 09:30 – 11:00 AM
**GLOBAL PHARMACEUTICAL
INDUSTRY AND ROLE OF PHARMACIST**
Mr. AMIT KHANNA
Director, Pharma Business Development, India, India

Time: 11:30 AM – 12:30 PM
**CAREER IN PHARMACOVIGILANCE
SCOPE AND OPPORTUNITIES**
Ms. LEKSHMI CHANDRAN
Senior Safety Specialist, BMS Biologics, Coimbatore, Bangalore

Time: 12:30 PM – 1:30 PM
**ROLE OF CLINICAL PHARMACIST
IN HOSPITAL SETTING**
Dr. MOHAMED HISHAM
Clinical Pharmacist, Dept. of Pharmacy Services, Government Hospital, Coimbatore

Register : www.amrita.lnk/pharma
Contact: Dr. M. S. Sudheesh, Coordinator
☎ 944572819 | ✉ pharmschool@am.amrita.edu

OBJECTIVE:

To induct the students to different career avenues in pharmacy. Experts from Industry, Pharmacovigilance and clinic explained the scope and opportunities in their respective fields.

HIGHLIGHTS:

- Mr. Amit Khanna spoke on the topic “Global Pharmaceutical Industry and the role of Pharmacist”. He provided glimpses on the functioning at various levels in a pharma industry set-up and the integrated role of different departments in ensuring quality medicines to all. He also enlightened the audience regarding the opportunities in the domestic & international pharma market.
- Ms. Lekshmi Chandran delivered a talk on “Career in Pharmacovigilance: Scope and Opportunities”.

She elaborate on the career avenues of Pharmacovigilance

- Dr. Mohamed Hisham deliberated on the topic “Role of Clinical Pharmacist in a Hospital Setting”. He focused on the core competence of a clinical pharmacist and the opportunities in different areas of clinical practice.

Teacher’s day Celebrations: 5th Sept 2020

THANK YOU DEAR TEACHER FOR
GIVING US KNOWLEDGE OF AND
PROVIDING US WITH A BETTER FUTURE

AMRITA School of Pharmacy

"A good teacher is like a candle -
it consumes itself to light the way for
others."

HAPPY TEACHERS DAY
5th SEPTEMBER 2020

HIGHLIGHTS:

- Pharm D 2018 batch students hosted the event.
- Video presentation as a tribute to teachers.
- Various entertainment programmes and games for teachers.

Webinar on 15th September 2020



AMRITA School of Pharmacy
ANCHROM HPTLC Application Since 1978

Date September 15, 2020
(Tuesday)

Webinar on:
HPTLC Techniques & Pharma Applications

Speaker: Mr. Vishwajit Kale
Application Specialist
Anchrom Enterprises Pvt. Ltd.

Register online at: <https://zoom.us/join/ajoin?u=98180575&pwd=98180575>

Click Here!

Contact:
Dr. Sathianarayanan, Coordinator
+91 9446042083
pharmapincipal@aims.amrita.edu

A certificate will be issued to the attendees after successful completion of the webinar

Mr. Vishwajit Kale is an analytical specialist especially in HPTLC.

HIGHLIGHTS

The session was very informative and he explained about the pharma, biomedical, forensic and herbal applications of HPTLC.

Webinar on 24th August 2020



AMRITA School of Pharmacy

You're Invited to Join
WEBINAR ON

**CLINICAL DRUG DEVELOPMENT AND
ROLE OF CLINICAL PHARMACOLOGY**

MON DAY | AUG 24 | 3 PM

Dr. Satyendra Suryawanshi
Director, Clinical Pharmacology & Pharmacometrics,
Bristol-Myers Squibb, Princeton, NJ, USA

Join Webinar on Google Meet : meet.google.com/tzsz-tufh-vpe

For Queries Contact : Dr. M. S. Sudheesh, Coordinator
Mob : 988372019
Email : msudheesh@aims.amrita.edu

Talk on Clinical drug development of oncology, cardiovascular and metabolic drugs: 24th August 2020.

Dr. Satyendra Suryawanshi, Director, Clinical Pharmacology & Pharmacometrics, Bristol-Myers Squibb, Princeton, NJ, USA.

HIGHLIGHTS

- Development process of biologics and their difference from small molecules.
- Role of pharmacokinetic models for pediatric dose calculations.
- The role of software used in clinical pharmacology

World Pharmacists day celebrations - 2020



DAY 1 - 23 SEPTEMBER 2020

Session I 10.30 am

Dr. RAO V.S.V. VADLAMUDI

President, Commonwealth Pharmacists Association (CPA)

Topic: "COVID-19 Resources available for pharmacy professionals from CPA"

Session II 03.00 pm

Dr. ABHIJITH K

Clinical Pharmacist, Department of Gastrointestinal Surgery and Liver transplant Amrita Institute of Medical Sciences and Research Centre, Kochi

Topic: "Clinical Pharmacist's Interventions in Critical Care and Liver transplant ICU"

DAY 2 - 24 SEPTEMBER 2020

Session I 09.00 am

Dr. SUJITH J CHANDY

Professor at the Dept. of Pharmacology & Clinical Pharmacology, and Administrative Head of Pharmacy, Christian Medical College, Vellore

Topic: "Medicines and Global health"

Session II 03.30 pm

Dr. VIVEKANANDAN KALAISELVANM

Principal Scientific Officer, Indian Pharmacopoeial Commission Ministry of Health & Family Welfare, Ghaziabad, UP

Topic: "Pharmacists' role in medical product safety surveillance - scope and contemporary challenges"

A webinar series was hosted by Amrita School of Pharmacy, Kochi in connection to World Pharmacists Day 2020 celebrations to promote the theme suggested by International Pharmaceutical Federation (FIP)- 'Transforming Global Health'. The 4 day series which began on 23rd September 2020 and ended on 26th September had spectra of 7 divergent sessions handled by experienced and enthusiastic pharmacy and health care professionals. The virtual platform witnessed the presence of more than 600 participants including in-house students and faculty as well as delegates of around 15

other pharmacy institutions within and outside the state of Kerala.

HIGHLIGHTS

- Day 1 (23/09/2020): The inaugural session was handled by Iconic pharmacy professional of India, Dr. Rao VSV Vadlamudi, who delivered an excellent session on 'COVID -19 Resources available for pharmacy professionals from CPA'.
- Second session of the day witnessed a young clinical pharmacist sharing the responsibilities, potentials and his experiences in a surgery

DAY 3 - 25 SEPTEMBER 2020

Session I 09.00 am

Ms. MANJU MATHAIRegd. Pharmacist (RPh), Jefferson
Northeast Hospital, Pennsylvania, USATopic: "Role of pharmacist in the
management of COPD"**DAY 4 - 26 SEPTEMBER 2020**

Session I 09.00 am

Mr. PRAVEEN MENONPartner (Regional Manager), Personalized
Health Care, Foundation Medicine-Roche,
New DelhiTopic: "Role of cancer genomics and
precision oncology in transforming
cancer care"

department of a tertiary care hospital.

• Day 2 (24/09/2020): Dr. Sujith Chandy, provided insights on 'Medicines & Global health'. It was a thought provoking session on the medicine related aspects affecting global health.

• A lecture on 'Pharmacists role in medical safety surveillance - scope and contemporary challenge' by dedicated government official Dr. V Kalaiselvam. The session was an eye opener to budding professionals about the opportunities awaiting them in the field of medical devices.

• Day 3 (25/09/2020): Ms. Manju Mathai explained about various therapeutical modalities used in COPD management and also shared about the perquisites and legal requirements for entering into pharmacy profession in USA.

• Day 4 (26/09/2020): Mr. Praveen Menon presented about the concepts of genomics and precision medicine and its future in the field of oncology. Mr. Deepak Singh and Mr. Mahesh Pooyath, provided insights on the new potential areas and domains that can be explored and excelled by the pharmacy professionals in coming future. Both the speakers added about the post graduate courses that could be fitted to different career profiles.

**DAY 4 - 26 SEPTEMBER 2020**

Session II 10.00 am

Mr. DEEPAK SINGHHead R & D (Sales), Genzyme India,
Mumbai

&

Mr. MAHESH POOYATHExecutive, R & D
Oncor Pharmaceuticals Products Co LLC,
Solihull, Oman
Topic: "New career arenas in Pharma
field & Pharmacists: Changing the
face of healthcare"

**WORLD
PHARMACISTS
DAY** 25 September

An inspiring talk



Webinar

Uncover your reason to get up in the morning

Sri. Peeyush G
Motivational Speaker

Amritavarsham 67

Thursday, Sep 24, 2020 11 AM IST

GOOGLE MEET:
<https://meet.google.com/dpu-sagg-pnw>

When you get up in the morning, let your first thought be directed towards God.
- Amma

As a part of Amritavarsham 67, our beloved Amma's auspicious birthday, a webinar was conducted in Amrita School of Pharmacy on September 24, 2020. The session was handled by Sri. Peeyush G and gave a very good talk on the topic 'Uncover your reason to get up in the morning'.

HIGHLIGHTS

- Discussion on a Japanese concept 'IKIGAI', which means 'a reason for being'.
- The concept told us to ask a few questions to ourselves. It includes, what you love, what the world needs, what you can be paid for, what you are good at.
- Asked everyone to find and follow their passion, mission, profession etc.

Webinar on 8th October 2020

DEPT. OF PHARMACOLOGY
SCHOOL OF PHARMACY

SMART LEARNING IN A NEW NORMAL

08 OCT 2020 | TIME: 10.00 AM & 02.30 PM

10 AM: THE CURIOUS CASE OF ONLINE LIVING

2.30 PM: ADDRESSING THE CHALLENGES OF ONLINE LEARNING

LINK: <https://zoom.us/j/960859666?pwd=K2RwThUwUWVhbnk5YTZURVZ5dD09>
Meeting ID: 960 855 9666
Passcode: 7900

Online e-Learning

SUDEEP SEBASTIAN
Digital Media Strategist | Executive Coach

PROF. SREEVALSAN MOOTHEDATH
Head - ICTS | Amrita Vishwa Vidyapeetham

KANTILAL @ +91 97874 10041

The corona virus is a wake-up call. We should try to see others' pain as our own, see them as a part of ourselves, and establish a heart-connection with them.
- AMMA

The department of Pharmacology conducted a webinar on Smart learning in a New Normal.

HIGHLIGHTS

- A session on "The curious case of online living" was taken by Sri Sudeep, Learning and Development Expert, Perception Management Specialist, NLP Practitioner. He discussed about the pros and cons of online living, ethics and cyber security.
- Another session on "Addressing the challenges of online learning" was handled by Prof. Sreevalsan Moothedath, Head ICT at Amrita Vishwa Vidyapeetham. During his session he discussed about how to learn in an online environment.



Inauguration of New Academic Batches -2020

Management, Principal, Staff and Students of Amrita School of Pharmacy cordially invite your presence for the INAUGURATION OF 2020 ACADEMIC BATCHES of B.Pharm, M.Pharm, Pharm.D Date : 4 th November 2020 • Time: 9.30 am - 12.30 pm	
9.30 am Embracing the world Video show	10.00 am Prayer and lamp lighting
10.10 am Welcome speech Dr. SABITHA M Principal, Amrita School of Pharmacy	10.20 am Welcome to Kochi Amrita Campus Bri. REHANA Administrator AIMS Hospital & Student Welfare
10.30 am Address by Chief Guest Dr. JASMIN JOHNSON Operational Head CSR-TCS Partnership (Clinical Services) Tata Consultancy Services, Mumbai	10.45 am Address by Dean Research Dr. SHANTIKUMAR V NAIR Dean Research Amrita Vishwa Vidyapeetham
11.00 am Benedictory address SAMPOOJYA SWAMI POORNAMRITANANDA PURI General Secretary Mada Amritanandaramayi Math	11.30 am Sharing of Campus experiences 1. Ms. Rakhi Krishna Pharm.D Alumina (2014-2020) 2. Ms. Adithya J B.Pharm 2 nd semester student
12.00 Noon Address by Guest of Honour Mr. ANSHU VERMA Associate Director, Third Party Operations and Project Management, Teva Pharmaceuticals, Mumbai	12.15 pm Vote of thanks Dr. VIDYA VISWANAD Asso. Professor Amrita School of Pharmacy

Amrita School of Pharmacy welcomed its 16th batch of B.Pharm, 11th batch of Pharm D and 13th Batch of MPharm on 4th November 2020 through the virtual platform. The welcome address was delivered by principal Dr. Sabitha M after the lamp lighting ceremony. The benedictory address was given by Sampoojya Swami Poornamritananda Puri, Bri. Rehanaji, welcomed the students to be part of Kochi campus. The chief guest of the day was Dr. Jasmin Johnson who gave an enlightening presentation regarding the role of pharmacy

professionals in the future of medicine. Mr. Anshu Verma He gave an informative speech regarding pharmacy professionals in the field of business management and marketing. Dr. Shantikumar V Nair, Dean Research, Amrita Vishwa Vidyapeetham also addressed the newcomers..

Cultural Festive Celebrations Navarathri 2020

AMRITA School of Pharmacy

നവരാത്രി നാളെപ്പറമ്പ് 2020

മഹാലാക്ഷ്മി വിഗ്രഹാരാധന

Dr. Lakshmi Shankar
 Assistant Professor, Sree Krishna College,
 Guruvayur and a member in the judging panel of the
 renowned program in Amrita TV,
 "Sreshtabharatham Mahabharatham", which
 inculcate human values into the audience.

THURSDAY, 22 OCTOBER 4:30 PM
<https://meet.google.com/mw-cxai-rvtn>

In connection with Navaratri Celebrations, Amrita School of Pharmacy arranged a talk on 22nd October handled by Dr. Lakshmi Shankar , Assistant Professor, Sree Krishna College, Guruvayur and a member in the judging panel of the renowned program in Amrita TV, "Sreshtabharatham Mahabharatham", which inculcate human values into the audience.

HIGHLIGHTS

- Dr. Lakshmi Shankar shared her knowledge about the significance of Navratri days. She spoke on a topic "The day and nights of refinement".
- The value and power of Lalithasahasranama and Devi Mahatmyam was discussed in the session.

New staff members

@Amrita School of Pharmacy

Dr.BIJO MATHEW

Associate Professor, Department of Pharmaceutical Chemistry



Dr. Bijo Mathew joined as Associate Professor in the department of Pharmaceutical Chemistry and Analysis. Dr. Bijo Mathew obtained his M.Pharm in Pharmaceutical

Chemistry from The Tamilnadu Dr. M. G. R. Medical University, Tamilnadu, India in 2008 and Ph.D. in Pharmaceutical Sciences from Jawaharlal Nehru Technological University, Hyderabad, India in 2016. Dr. Mathew's primary areas of focus are in drug discovery for neurodegenerative disorders, cancer and molecular modelling. His main research interest is on the design of enzyme inhibitors, and especially monoamine oxidase and acetylcholinesterase inhibitors. He has published

136 papers, [h-index = 25; the number of citations: 1738 in Google scholar; h-index = 24; the number of citations: 1500 in Scopus [November 2020]. With 13 years of teaching and research experience, Mathew authored 1 book, edited 1 book, 5 book chapters and has delivered 25 invited talks in national as well as international conferences. Dr. B. Mathew is serving as a chief executive guest editor of the journals of Current Drug Targets, Journal of Chemistry, and Combinatorial Chemistry and High Throughput Screening. He is a Section Editor of the journal of Coronaviruses [Bentham Science]. He received one patent from Korean Intellectual Property of Office in the topic of protective or therapeutic compositions of neurological disorders containing furano chalcones as effective agents.




AMRIT SAGAR MOHAN

Manager - Corporate Relations

Mr. Amrit Sagar Mohan has got 4.5 years experience as manager in corporate sales, marketing, digital marketing, handling negotiations, mentorship and events management. He has completed his M.B.A from Amrita School of Business in the area of

marketing and operations. His credits include collaborative team player, having superior problem solving abilities, entrepreneurial experience and also a proven track record of managing startup support ecosystem, organizing incubation and acceleration program.

Placements @ Amrita School of Pharmacy



Outstanding placements by Covance, TCS life Sciences, IQVIA, Apollo Hospital and Indegene Pvt Ltd.

A wide array of profiles was offered in Drug Manufacturing, Industrial Research, Analytics,

Sales & Marketing, Clinical Pharmacist, Pharmacovigilance. Top profiles as Safety Science Analysts, Senior Executive-Drug Safety, Quality Assurance, Junior Associate- Scientific Writing, Safety Associate Trainee and Senior Hospital Pharmacist.



AMRITA
VISHWA VIDYAPEETHAM
DEEMED TO BE UNIVERSITY

School of
Pharmacy

for comments & suggestions:

Amrita School of Pharmacy

Amrita Vishwa Vidyapeetham, AIMS Ponekkara, Kochi - 682 041, Kerala, India

Phone : 0484-2857900/ 03 /04, 0484-2802020 (Fax)

Email : pharmaprincipal@aims.amrita.edu, pharmacycollege@aims.amrita.edu

Website: <https://www.amrita.edu/school/pharmacy>

CHIEF EDITOR
Dr. Sabitha M, Principal

EDITORIAL BOARD
Dr. S Sathianarayanan
Dr. M.S. Sudheesh
Ms. Remya Reghu
Ms. Anila K.N.

PUBLISHED BY
Amrita School of Pharmacy
Amrita Vishwa Vidyapeetham,
Kochi- 682 041, Kerala, India

FOLLOW US ON

www.facebook.com/amritapharmaschool twitter.com/AMRITAedu [instagram.com/amritapharmacy](https://www.instagram.com/amritapharmacy)